BRCA1 and BRCA2 are genes involved in DNA repair and they prevent tumor growth. ACTBRCA™ is a test that detects genetic alterations in BRCA1 and BRCA2.
These alterations provide information about therapeutic options and also the risk of developing certain cancer types or cancer recurrence. BRCA1 and BRCA2 somatic mutations could be identified in 3 – 9% of the unselected ovarian cancer specimen(Note 1) and 3% of breast cancer specimen(Note 2). Studies have shown that BRCA mutations are significant predictors for the efficacy of targeted therapy in breast and ovarian cancers (Note 3).
It is also known that inherited BRCA mutation carriers are at a higher risk of developing breast cancer (54-85%), ovarian cancer (40-60%), prostate cancer (20%),
and pancreatic cancer (5%) (Note4)
Note1. Hennessy et al., J Clin Oncol., 28:3570-3576 (2010)
Note2. Nik-Zainal et al., Nature, 534:47-54 (2016)
Note3. Zong et al., Clin Cancer Res., 21:211-220 (2015)
Note4. Garber JE., (Update on screening and surveillance in BRCA1/2 carriers) 2015 ASCO Annual Meeting